with the support of the Agnelli family

Title. Last May, we returned to take a position on BioMérieux, which was then trading at 83 Euros. The title has since rebounded to evolve now above the threshold of 100 Euros… This support is linked to the entry of Exor into the capital of Institut Mérieux, which is the reference shareholder of the diagnostics specialist. in vitro with 59% of the titles in his possession. Until now, Mérieux held all of the shares in Institut Mérieux. Through a reserved capital increase of 833 million Euros, Exor will become the owner of 10% of the head office of the Mérieux galaxy.